PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)

Completed

Conditions: Ulcerative Colitis
Crohn's Disease

Interventions: Drug: Infliximab [infliximab biosimilar 3]

First Posted Date: 2019-03-21

Last Posted Date: 2025-03-21

Lead Sponsor: Pfizer

Target Recruit Count: 428

Registration Number: NCT03884439

Locations: 🇯🇵
Pfizer Local Country Office, Tokyo, Japan

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Infliximab [infliximab biosimilar 3]

First Posted Date: 2019-03-21

Last Posted Date: 2025-04-13

Lead Sponsor: Pfizer

Target Recruit Count: 77

Registration Number: NCT03885037

Locations: 🇯🇵
Pfizer Local Country Office, Tokyo, Japan

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)

Completed

Conditions: Psoriasis Arthropathica
Pustular Psoriasis
Erythrodermic Psoriasis
Psoriasis Vulgaris

Interventions: Drug: Infliximab [infliximab biosimilar 3]

First Posted Date: 2019-03-21

Last Posted Date: 2024-03-22

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT03885089

Locations: 🇯🇵
Pfizer Local Country Office, Tokyo, Japan

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: binimetinib
Drug: encorafenib

First Posted Date: 2019-03-18

Last Posted Date: 2023-04-03

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT03878719

Locations: 🇮🇹
Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Lombardy, Italy

Acute Treatment Trial in Adult Subjects With Migraines

Phase 2

Completed

Conditions: Migraine

Interventions: Drug: Zavegepant
Drug: Zavegepant matching placebo
Device: Intranasal Aptar Pharma Unit Dose System

First Posted Date: 2019-03-13

Last Posted Date: 2023-09-25

Lead Sponsor: Pfizer

Target Recruit Count: 2154

Registration Number: NCT03872453

Locations: 🇺🇸
CT Clinical Research, Cromwell, Connecticut, United States
🇺🇸
Elite Clinical Studies, Phoenix, Arizona, United States
🇺🇸
Optimus Medical Group, San Francisco, California, United States

and more 72 locations

OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-05221304 Formulation B
Drug: PF-05221304 Formulation A

First Posted Date: 2019-03-12

Last Posted Date: 2020-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT03871439

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Metastatic Melanoma
Advanced Solid Tumors

Interventions: Drug: losartan
Drug: rosuvastatin
Drug: bupropion immediate release (IR)
Drug: dextromethorphan
Drug: caffeine
Drug: modafinil
Drug: omeprazole
Drug: midazolam
Drug: encorafenib
Drug: binimetinib

First Posted Date: 2019-03-06

Last Posted Date: 2023-06-08

Lead Sponsor: Pfizer

Target Recruit Count: 56

Registration Number: NCT03864042

Locations: 🇨🇦
Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
🇺🇸
UC Irvine Health, Orange, California, United States
🇺🇸
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States

and more 26 locations

Evaluate Severe Hepatic Impairment on Dacomitinib PK

Phase 1

Completed

Conditions: Severe Hepatic Impairment

Interventions: Drug: Dacomitinib

First Posted Date: 2019-03-06

Last Posted Date: 2020-11-06

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT03865446

Locations: 🇺🇸
Investigational Drug Services (IDS) University of Miami Hospitals and Clinics, Research Pharmacy, Miami, Florida, United States
🇺🇸
University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Study Evaluating the Effects of PSI-697 on Platelets in Subjects Who Smoke

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PSI-697
Drug: Placebo

First Posted Date: 2019-03-04

Last Posted Date: 2019-03-04

Lead Sponsor: Pfizer

Target Recruit Count: 30

Registration Number: NCT03860506

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B

Phase 3

Active, not recruiting

Conditions: Hemophilia B

Interventions: Biological: PF-06838435/ fidanacogene elaparvovec

First Posted Date: 2019-03-04

Last Posted Date: 2025-04-17

Lead Sponsor: Pfizer

Target Recruit Count: 51

Registration Number: NCT03861273

Locations: 🇩🇪
Vivantes Klinikum Friedrichshain, Berlin, Germany
🇩🇪
Vivantes Klinikum im Friedrichshain, Berlin, Germany
🇩🇪
Universitaetsklinikum Bonn, Bonn, Germany

and more 56 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy